Galapagos to hold Annual R&D Update 2017 on 20 June
May 17 2017 - 1:30AM
Mechelen,
Belgium; 17 May 2017; 7.30 CET - Galapagos NV
(Euronext & NASDAQ: GLPG) announces it will hold its Annual
R&D Update 2017 on 20 June at 8 AM EDT at the Yale Club in New
York City. This event will also be webcast.
Each year, Galapagos presents its
progress in discovering and developing therapies with novel modes
of action to shareholders, investors, banks, and the media. This
year's event will feature updates on selective JAK1 inhibitor
filgotinib, currently in multiple Phase 2 and Phase 3 studies, and
on the triple combination therapy development in cystic fibrosis.
Galapagos will further highlight progress in its other partnered
and proprietary programs, including earlier stage assets moving
forward.
Please RSVP to susan@sanoonan.com
to reserve your place at breakfast starting at 7:30 AM
EDT/13.30 CET at the Yale Club, 50 Vanderbilt Ave, NY on 20
June 2017. The event also will be webcast starting at 8 AM
EDT/14.00 CET, to be accessed via www.glpg.com.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage
biotechnology company specialized in the discovery and development
of small molecule medicines with novel modes of action. Our
pipeline comprises Phase 3, Phase 2, Phase 1, pre-clinical, and
discovery programs in cystic fibrosis, inflammation, fibrosis,
osteoarthritis and other indications. We have discovered and
developed filgotinib: in collaboration with Gilead we aim to bring
this JAK1-selective inhibitor for inflammatory indications to
patients all over the world. Galapagos is focused on the
development and commercialization of novel medicines that will
improve people's lives. The Galapagos group, including
fee-for-service subsidiary Fidelta, has approximately 530
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. More
information at www.glpg.com.
Contacts
Investors: |
Media: |
Elizabeth Goodwin |
Evelyn Fox |
VP IR & Corporate Communications |
Director Communications |
+1 781 460 1784
Paul van der Horst
Director IR & Business Development
+31 6 53 725 199 |
+31 6 53
591 999
communications@glpg.com |
ir@glpg.com |
|
Forward-looking
statements
This release may
contain forward-looking statements, including statements regarding
Galapagos' strategic ambitions, the anticipated timing of clinical
studies with product candidates and the progress and results of
such studies. Galapagos cautions the reader that forward-looking
statements are not guarantees of future performance.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors which might cause the actual
results, financial condition and liquidity, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions
and liquidity, performance or achievements expressed or implied by
such forward-looking statements. In addition, even if Galapagos'
results, performance, financial condition and liquidity, and the
development of the industry in which it operates are consistent
with such forward-looking statements, they may not be predictive of
results or developments in future periods. Among the factors that
may result in differences are the inherent uncertainties associated
with competitive developments, clinical trial and product
development activities and regulatory approval requirements
(including that data from the ongoing and planned clinical research
programs may not support registration or further development of
product candidates due to safety, efficacy or other reasons),
Galapagos' reliance on collaborations with third parties (including
its collaboration partner for filgotinib, Gilead, and with its
collaboration partner for cystic fibrosis, AbbVie), and estimating
the commercial potential of Galapagos' product candidates. A
further list and description of these risks, uncertainties and
other risks can be found in Galapagos' Securities and Exchange
Commission (SEC) filings and reports, including in Galapagos' most recent annual report on form 20-F filed
with the SEC and subsequent filings and reports filed by Galapagos
with the SEC. Given these uncertainties, the reader is advised not
to place any undue reliance on such forward-looking statements.
These forward-looking statements speak only as of the date of
publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statement is based or that may affect the likelihood
that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or
regulation.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Galapagos NV via Globenewswire
Galapagos NV (NASDAQ:GLPG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galapagos NV (NASDAQ:GLPG)
Historical Stock Chart
From Apr 2023 to Apr 2024